# Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

> **NCT02346721** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 111 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** SOF/VEL

## Key facts

- **NCT ID:** NCT02346721
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-23
- **Primary completion:** 2016-03-23
- **Final completion:** 2016-06-15
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02346721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02346721, "Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02346721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*